Table 1.
Patient characteristics.
| Variables | Overall, n (%) |
CRT Group, n (%) |
Non-CRT Group, n (%) |
p-Value | |
|---|---|---|---|---|---|
| No. of patients | 26 (100) | 8 (31) | 18 (69) | ||
| Age (years) | 74 (36–87) | 74 (46–86) | 76 (36–87) | 0.96 | |
| Sex | Male | 19 (73) | 8 (100) | 11 (61) | 0.039 |
| Female | 7 (27) | 0 (0) | 7 (39) | ||
| ECOG PS | 0–1 | 23 (88) | 7 (88) | 16 (89) | 0.92 |
| ≥2 | 3 (12) | 1 (13) | 2 (11) | ||
| Primary site | Bladder | 18 (69) | 8 (100) | 10 (56) | 0.023 |
| UUT | 8 (31) | 0 (0) | 8 (44) | ||
| Lymph node metastasis | No | 7 (21) | 1 (13) | 6 (33) | 0.27 |
| Yes | 19 (73) | 7 (88) | 12 (67) | ||
| Visceral metastasis | No | 11 (42) | 2 (25) | 9 (50) | 0.23 |
| Yes | 15 (58) | 6 (75) | 9 (50) | ||
| Previous curative surgery | No | 15 (42) | 5 (63) | 10 (56) | 0.74 |
| Yes | 11 (58) | 3 (38) | 8 (44) | ||
| Line of pembrolizumab | 2nd | 23 (88) | 7 (88) | 16 (89) | 0.92 |
| 3rd or later | 3 (12) | 1 (13) | 2 (11) |
Abbreviations: CRT, chemoradiotherapy; ECOG PS; Eastern Cooperative Oncology Group Performance Status; UUT, upper urinary tract.